Genomic Characterization of Metformin Hepatic Response

PLoS Genetics

Volumn 12, Issue 11, 2016, Pages

  Luizon, Marcelo R ^a,b   Eckalbar, Walter L ^a   Wang, Yao ^a,c   Jones, Stacy L ^a   Smith, Robin P ^a   Laurance, Megan ^a   Lin, Lawrence ^a   Gallins, Paul J ^d   Etheridge, Amy S ^e   Wright, Fred ^d   Zhou, Yihui ^d   Molony, Cliona ^f   Innocenti, Federico ^e   Yee, Sook Wah ^a   Giacomini, Kathleen M ^a   Ahituv, Nadav ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c TSINGHUA UNIVERSITY   (China)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; HISTONE H3; METFORMIN; ACTIVATING TRANSCRIPTION FACTOR 3; ATF3 PROTEIN, HUMAN; ATM PROTEIN, HUMAN; DDX10 PROTEIN, HUMAN; DEAD BOX PROTEIN; EXPH5 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG RESPONSE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIATION; GENOME ANALYSIS; HAPLOTYPE; HUMAN; HUMAN CELL; INTRON; LIVER CELL; PROMOTER REGION; QUANTITATIVE TRAIT LOCUS; RNA SEQUENCE; UPREGULATION; BIOSYNTHESIS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENHANCER REGION; GENE SILENCING; GENETICS; GLUCONEOGENESIS; LIVER; METABOLISM; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ACTIVATING TRANSCRIPTION FACTOR 3; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMP-ACTIVATED PROTEIN KINASES; ATAXIA TELANGIECTASIA MUTATED PROTEINS; DEAD-BOX RNA HELICASES; DIABETES MELLITUS, TYPE 2; ENHANCER ELEMENTS, GENETIC; GENE KNOCKDOWN TECHNIQUES; GLUCONEOGENESIS; HAPLOTYPES; HEPATOCYTES; HUMANS; LINKAGE DISEQUILIBRIUM; LIVER; METFORMIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85000501101     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006449     Document Type: Article

References (76)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2015) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care38: 140–149. doi: 10.2337/dc14-244125538310
2. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, et al. (2015) American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome—Part 1. Endocr Pract21: 1291–1300. doi: 10.4158/EP15748.DSC26509855
3. Zhao LP, Sheng XY, Zhou S, Yang T, Ma LY, et al. (2015) Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol80: 1224–1234. doi: 10.1111/bcp.1267225925501
4. Boland CL, Harris JB, Harris KB, (2015) Pharmacological management of obesity in pediatric patients. Ann Pharmacother49: 220–232. doi: 10.1177/106002801455785925366340
5. He H, Ke R, Lin H, Ying Y, Liu D, et al. (2015) Metformin, an old drug, brings a new era to cancer therapy. Cancer J21: 70–74. doi: 10.1097/PPO.000000000000010325815846
6. Pernicova I, Korbonits M, (2014) Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol10: 143–156. doi: 10.1038/nrendo.2013.25624393785
7. Turner RC, Cull CA, Frighi V, Holman RR, (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA281: 2005–2012. 10359389
8. Cook MN, Girman CJ, Stein PP, Alexander CM, (2007) Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med24: 350–358. doi: 10.1111/j.1464-5491.2007.02078.x17335466
9. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B, (2014) Metformin: from mechanisms of action to therapies. Cell Metab20: 953–966. doi: 10.1016/j.cmet.2014.09.01825456737
10. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, et al. (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes49: 2063–2069. 11118008
11. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest108: 1167–1174. doi: 10.1172/JCI1350511602624
12. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, et al. (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond)122: 253–270.
13. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science310: 1642–1646. doi: 10.1126/science.112078116308421
14. Kim YD, Park KG, Lee YS, Park YY, Kim DK, et al. (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes57: 306–314. doi: 10.2337/db07-038117909097
15. Lee JM, Seo WY, Song KH, Chanda D, Kim YD, et al. (2010) AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J Biol Chem285: 32182–32191. doi: 10.1074/jbc.M110.13489020688914
16. He L, Sabet A, Djedjos S, Miller R, Sun X, et al. (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell137: 635–646. doi: 10.1016/j.cell.2009.03.01619450513
17. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest120: 2355–2369. doi: 10.1172/JCI4067120577053
18. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, et al. (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature494: 256–260. doi: 10.1038/nature1180823292513
19. Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, et al. (2014) Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol2: 481–487. doi: 10.1016/S2213-8587(14)70050-624731673
20. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE, (2012) Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics22: 820–827. doi: 10.1097/FPC.0b013e3283559b2222722338
21. Todd JN, Florez JC, (2014) An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics15: 529–539. doi: 10.2217/pgs.14.2124624919
22. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, et al. (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther83: 273–280. doi: 10.1038/sj.clpt.610027517609683
23. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, et al. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest117: 1422–1431. doi: 10.1172/JCI3055817476361
24. Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, et al. (2014) Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther96: 370–379. doi: 10.1038/clpt.2014.10924853734
25. GoDartsGroup UDPSWellcome Trust Case Control CZhou K, Bellenguez C, et al. (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet43: 117–120. doi: 10.1038/ng.73521186350
26. van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, et al. (2012) A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia55: 1971–1977. Epub 02012 Mar 00128. doi: 10.1007/s00125-012-2537-x22453232
27. Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, et al. (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet48: 1055–1059. Epub 2016 Aug 1058. doi: 10.1038/ng.363227500523
28. Kimura H, (2013) Histone modifications for human epigenome analysis. J Hum Genet58: 439–445. doi: 10.1038/jhg.2013.6623739122
29. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, et al. (2011) Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia54: 3101–3110. Epub 02011 Sep 00123. doi: 10.1007/s00125-011-2311-521947382
30. Igarashi Y, Nakatsu N, Yamashita T, Ono A, Ohno Y, et al. (2015) Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res43: D921–927. doi: 10.1093/nar/gku95525313160
31. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, et al. (2010) AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol45: 276–295. doi: 10.3109/10409238.2010.48821520522000
32. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, et al. (2010) GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol28: 495–501. doi: 10.1038/nbt.163020436461
33. Simonet WS, Bucay N, Lauer SJ, Taylor JM, (1993) A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem268: 8221–8229. 7681840
34. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, et al. (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell154: 442–451. doi: 10.1016/j.cell.2013.06.04423849981
35. Hashimoto Y, Zhang C, Kawauchi J, Imoto I, Adachi MT, et al. (2002) An alternatively spliced isoform of transcriptional repressor ATF3 and its induction by stress stimuli. Nucleic Acids Res30: 2398–2406. 12034827
36. Thompson MR, Xu D, Williams BR, (2009) ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl)87: 1053–1060.
37. Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, et al. (2014) Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J Biol Chem289: 23246–23255. doi: 10.1074/jbc.M114.57790824973221
38. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc4: 44–57. doi: 10.1038/nprot.2008.21119131956
39. Birkenfeld AL, Lee HY, Majumdar S, Jurczak MJ, Camporez JP, et al. (2011) Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolism. J Biol Chem286: 36163–36170. doi: 10.1074/jbc.M111.22881721832042
40. Lawandi J, Tao C, Ren B, Williams P, Ling D, et al. (2015) Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells. Mol Ther Methods Clin Dev2: 15011. doi: 10.1038/mtm.2015.1126029722
41. Yang J, Kalhan SC, Hanson RW, (2009) What is the metabolic role of phosphoenolpyruvate carboxykinase?J Biol Chem284: 27025–27029. doi: 10.1074/jbc.R109.04054319636077
42. Bechmann LP, Vetter D, Ishida J, Hannivoort RA, Lang UE, et al. (2013) Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol58: 1000–1006. doi: 10.1016/j.jhep.2013.01.02023353867
43. Feng Y, Longmore GD, (2005) The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex. Mol Cell Biol25: 4010–4022. doi: 10.1128/MCB.25.10.4010-4022.200515870274
44. Xie Z, Dong Y, Zhang J, Scholz R, Neumann D, et al. (2009) Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. Mol Cell Biol29: 3582–3596. doi: 10.1128/MCB.01417-0819414597
45. Lu XJ, Shi Y, Chen JL, Ma S, (2015) Kruppel-like factors in hepatocellular carcinoma. Tumour Biol36: 533–541. doi: 10.1007/s13277-015-3127-625652467
46. Enomoto M, Kizawa D, Ohsawa S, Igaki T, (2015) JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity. Dev Biol403: 162–171. doi: 10.1016/j.ydbio.2015.05.00125967126
47. Sun J, Zhao M, Jia P, Wang L, Wu Y, et al. (2015) Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action. PLoS Comput Biol11: e1004202. doi: 10.1371/journal.pcbi.100420226083494
48. Patterson KI, Brummer T, O'Brien PM, Daly RJ, (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J418: 475–489. 19228121
49. Bermudez O, Pages G, Gimond C, (2010) The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol299: C189–202. doi: 10.1152/ajpcell.00347.200920463170
50. Wang X, Chrysovergis K, Kosak J, Kissling G, Streicker M, et al. (2014) hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling. Aging (Albany NY)6: 690–704.
51. Liang X, Chien HC, Yee SW, Giacomini MM, Chen EC, et al. (2015) Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm12: 4301–4310. doi: 10.1021/acs.molpharmaceut.5b0050126528626
52. Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, et al. (2010) Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol205: 97–106. doi: 10.1677/JOE-09-034520093281
53. Luizon MR, Ahituv N, (2015) Uncovering drug-responsive regulatory elements. Pharmacogenomics16: 1829–1841. doi: 10.2217/pgs.15.12126555224
54. Smith RP, Lam ET, Markova S, Yee SW, Ahituv N, (2012) Pharmacogene regulatory elements: from discovery to applications. Genome Med4: 45. doi: 10.1186/gm34422630332
55. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, et al. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature437: 1109–1111. doi: 10.1038/nature0396716148943
56. Eicher JD, Landowski C, Stackhouse B, Sloan A, Chen W, et al. (2015) GRASP v2.0: an update on the Genome-Wide Repository of Associations between SNPs and phenotypes. Nucleic Acids Res43: D799–804. doi: 10.1093/nar/gku120225428361
57. Irvin MR, Wineinger NE, Rice TK, Pajewski NM, Kabagambe EK, et al. (2011) Genome-wide detection of allele specific copy number variation associated with insulin resistance in African Americans from the HyperGEN study. PLoS One6: e24052. doi: 10.1371/journal.pone.002405221901158
58. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet42: 105–116. doi: 10.1038/ng.52020081858
59. Zhao J, Li X, Guo M, Yu J, Yan C, (2016) The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation. BMC Genomics17: 335. doi: 10.1186/s12864-016-2664-827146783
60. Tebbe C, Chhina J, Dar SA, Sarigiannis K, Giri S, et al. (2014) Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget5: 4746–4764. doi: 10.18632/oncotarget.201224970804
61. Allen-Jennings AE, Hartman MG, Kociba GJ, Hai T, (2002) The roles of ATF3 in liver dysfunction and the regulation of phosphoenolpyruvate carboxykinase gene expression. J Biol Chem277: 20020–20025. doi: 10.1074/jbc.M20072720011916968
62. Lin C, Shi J, Moore A, Khetani SR, (2016) Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes. Drug Metab Dispos44: 127–136. Epub 062015 Oct 066029. doi: 10.1124/dmd.115.06602726452722
63. Dunn JC, Yarmush ML, Koebe HG, Tompkins RG, (1989) Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. Faseb J3: 174–177. 2914628
64. Meley D, Bauvy C, Houben-Weerts JH, Dubbelhuis PF, Helmond MT, et al. (2006) AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem281: 34870–34879. doi: 10.1074/jbc.M60548820016990266
65. Smith RP, Eckalbar WL, Morrissey KM, Luizon MR, Hoffmann TJ, et al. (2014) Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet10: e1004648. doi: 10.1371/journal.pgen.100464825275310
66. Kim D, Langmead B, Salzberg SL, (2015) HISAT: a fast spliced aligner with low memory requirements. Nat Methods12: 357–360. doi: 10.1038/nmeth.331725751142
67. Anders S, Pyl PT, Huber W, (2015) HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics31: 166–169. doi: 10.1093/bioinformatics/btu63825260700
68. Love MI, Huber W, Anders S, (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol15: 550. doi: 10.1186/s13059-014-0550-825516281
69. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol9: R137. doi: 10.1186/gb-2008-9-9-r13718798982
70. Quinlan AR, Hall IM, (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics26: 841–842. doi: 10.1093/bioinformatics/btq03320110278
71. Ward LD, Kellis M, (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res40: D930–934. doi: 10.1093/nar/gkr91722064851
72. Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, et al. (2011) Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet7: e1002078. doi: 10.1371/journal.pgen.100207821637794
73. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol6: e107. doi: 10.1371/journal.pbio.006010718462017
74. Schroder A, Klein K, Winter S, Schwab M, Bonin M, et al. (2013) Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J13: 12–20. doi: 10.1038/tpj.2011.4422006096
75. Xia K, Shabalin AA, Huang S, Madar V, Zhou YH, et al. (2012) seeQTL: a searchable database for human eQTLs. Bioinformatics28: 451–452. doi: 10.1093/bioinformatics/btr67822171328
76. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, et al. (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol32: 1262–1267. Epub 2014 Sep 1263. doi: 10.1038/nbt.302625184501